1800 244 735

Helpline (02) 9874 9777

Oz Buzz Updates: Day 2

Our second daily report from the Huntington’s disease World Congress brings together all the live updates from our twitter feed. Video of the day’s Oz Buzz session – with news, interviews and features – will be available to watch at HDBuzz.net later this week.

Tuesday, September 13, 2011

8:44 – G'day from Melbourne: day 2 of the Huntington’s Disease World Congress. Video of yesterday’s live Oz Buzz session is now on youtube.com/user/hdbuzzfeed

8:57 – Once we have drugs, how do we know how much to give people? Karl Kieburtz suggests some techniques.

9:05 – We’ll be interviewing Robert Pacifici, Chief Scientific Officer of CHDI live on stage later. Send your questions about drugs & trials!

9:12 – ‘There is nothing more precious to a drug hunter than an observation made in the population you want to treat’ Robert Pacifici, CHDI

9:15 – So sign up for observational trials! PREDICT-HD and TRACK-HD are two options

9:31 – Another observational trial to consider – ENROLL-HD

9:33 – ‘There’s no such thing as a good or bad animal model of HD’ – they all tell us useful things about different aspects – Pacifici

9:34 – We must understand how our experimental drugs work, and what problems they’re targeting, if we’re to test them successfully – Pacifici

9:46 – Joaquim Ferreira – It’s time to face challenge of how to do drug trials in ppl with the Huntington’s disease mutation but no symptoms

9:48 – Ferreira – designing trials carefully can help us tell the difference between effects on symptoms, and altering the progression of HD

9:52 – Studies like PREDICT, TRACK and ENROLL are crucial for getting to trials in pre-onset HD, & getting enough participants – Ferreira

9:59 – Drug regulatory agencies are willing to consider new rules for testing drugs in HD before symptom onset – if the community is on board

10:04 – “There are an impressive number of things moving towards trials that were specifically designed with Huntington’s in mind” – Pacifici

10:47 – Jeff: Steve Finkbeiner has built robot microscopes to understand how mutant huntingtin kills cells. Really cool.

10:51 – Jeff is now reporting from the session on ‘Basic science: protein homeostasis’. Ed reporting on ‘Biomarkers’

10:53 – Ed: Functional MRI scanning reveals important brain changes in pre-onset HD. Could be important for PreHD trials- Dr Nellie Georgiou

11:02 – Jeff: Question your assumptions. Steve Finkbeiner says that things we once thought bad for neurons might actually be protecting them

11:07 – Ed: Brain scans have helped develop drugs in diseases like Parkinson’s and Alzheimer’s. We can learn from that – Dr Rachael Scahill

11:21 – Ed: TRACK-HD results show that the earliest brain changes in HD mutation carriers may be in the ‘white matter’ connections – Scahill

11:23 – Jeff: Danny Hatter has built labels that let scientists follow the huntingtin protein around in live cells

11:25 – Ed: More TRACK-HD results: shrinkage in specific brain areas is linked to movement control. Again, may help us test drugs – Scahill

11:28 – Ed: “It takes a lot of sleuthing to get measurements precise enough to reveal the effects of drugs” – Prof Julie Stout

11:38 – Ed: We’re “not too far off” being able to detect drug benefits on thinking skills in HD mutation carriers – Stout

11:40 – Jeff: Bev Davidson is working to develop “RNAi” therapies, which turn off the mutant huntingtin protein

11:42 – Jeff: Bev: Even partial reduction of mutant huntingtin has beneficial effects in HD mice – we don’t need to completely ‘silence’ it.

11:50 – Ed: TRACK-HD and ‘CAB’ project are giving us a toolkit of reliable & meaningful tests for studying cognitive problems in HD – Stout

11:58 – Jeff: Bev has been testing ‘RNAi’ silencing in monkeys, a critical step to setting up human trials. Results show beneficial effects

12:04 – Ed: Huntington’s involves many cell types, not just neurons – including immune system. A whole-body disease – Prof Paul Muchowski #WHCD

12:07 – Jeff: Ralf Reilmann and TRACK-HD have developed machines to measure subtle motor problems in HD, like tongue strength

12:11 – Ed: KMO inhibitor drug, acting on blood immune cells, extends lifespan of HD mice – Muchowski

12:12 – Jeff: Reilmann – subtle changes in movements occur early in people carrying the HD mutation, before the onset of full-blown HD

12:14 – Ed: Muchowski also working on drugs to target ‘cannabinoid’ receptors (there’s no direct evidence for marijuana benefits in HD though)

12:18 – Ed: HD mice genetically engineered to lack ‘CB2’ cannabinoid receptors perform worse on tests of movement function – Muchowski

12:21 – Jeff: Reilmann – novel machines to measure HD movement symptoms are already being used in a human HD drug trial in Europe

12:22 – Ed: Breaking news. a drug that activates CB2 receptors improves motor function and prolongs the lifespan of HD mice – Muchowski

12:23 – Ed: CB2 activator drug even improves symptoms in ‘late stage’ mice – Muchowski

12:24 – Ed: Surprisingly the CB2 receptor isn’t found in the brain – meaning the CB2 drug may be acting in the blood, like the KMO inhibitor

12:28 – Ed: Targeting the immune system directly with an antibody to the immune signaling molecule IL6 produces similar benefits – Muchowski

12:47 – Ed: Working in HD fruit flies, Juan Botas found calcium changes. Now using data networks to work out what it means for patients

13:52 – Ed now reporting from the ‘clinical care research’ session. Jeff reporting from ‘Basic science: systems & peripheral pathology’

13:55 – Jeff: Maria Bjorkqvist – HD is a whole body disease, not just a brain disease. Patients have problems in bone, fat, muscle & others

13:56 – Ed: Regular patient/carer education sessions improve anxiety, mood, coping strategies and quality of life in HD – Prof Raymund Roos

14:00 – Ed: Roos – We must not hide from difficult issues like end-of-life care and suicide. Silence is the enemy. Keep talking.

14:03 – Jeff: Bjorkqvist – Heart attacks kill a large percentage of HD patients – this could this be part of the disease, not coincidence

14:14 – Jeff: Richard Faull – People with HD have diverse symptoms, which causes different patterns of brain cell loss

14:16 – Jeff: Faull – Donated human brains from HD patients are a precious gift to scientists studying the disease

14:27 – Ed: Dr David Craufurd: We have good treatments for psychiatric problems in HD e.g. depression, anxiety & aggression. Speak to your doc!

14:47 – Jeff: George Rebec records the firing of brain cells from awake mice, and can see clear changes in firing patterns in HD mice

14:53 – Ed: Problems recognizing other people’s emotions are more widespread than previously thought in HD patients – Izelle Labuschagne

15:17 – Ed: Nobody can handle HD alone – true of at-risk people and care professionals – it takes a great team from early on – Dr Martha Nance

15:20 – Jeff: William Yang-Building mice with mutant huntingtin in limited brain areas to understand what parts of brain are important in HD

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Meeting 2021

Published date: 28 October, 2021

Last month, the Huntington’s disease (HD) research community, patients and other stakeholders met online at the European Huntington’s disease network (EHDN) conference. Despite the ongoing global pandemic, there is a tremendous amount of work underway in labs and clinics around the world as researchers continue to better understand HD and how we might best treat ... Read more

Real talk: Q&A with Roche about GENERATION-HD1

Published date: 28 September, 2021

At the end of day 1 of the European Huntington’s Disease Network (EHDN) conference, the HDBuzz team (minus one) sat down for a zoom chat with the team at Roche to have a frank, candid discussion about the recent halting of GENERATION-HD1, the Phase 3 clinical trial that was testing the ability of the antisense ... Read more

Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing

Published date: 30 August, 2021

A team of scientists recently created an innovative genetic system where a drug taken by mouth could be used to control the action of a gene editor, like those used in CRISPR systems. This has useful applications for research studies in cells and animals, and perhaps most importantly, could lead to improvements in the safety ... Read more

Unpacking recent gene therapy press

Published date: 16 August, 2021

A recent announcement from Voyager Therapeutics outlined a shift in the company’s strategy towards an exciting new technology for gene therapy delivery. Unfortunately this also means that in the short term, they have dropped previous plans to test an HD gene therapy in people with HD. While this news is disappointing, the decision to embrace ... Read more

Does blood hold the key to testing treatments earlier in HD patients?

Published date: 4 August, 2021

Researchers at Johns Hopkins led by Wenzhen Duan have developed a non-invasive way to track progression of Huntington’s disease (HD) which could be used before patients even start showing symptoms. Using a type of brain scan called an MRI, the researchers have shown that in mouse models of HD they can accurately measure the amount ... Read more

A first for CRISPR gene editing could have wider applications for human disease

Published date: 21 July, 2021

A recent clinical trial successfully tested the safety of CRISPR gene editing to reduce the amount of a toxic protein in patients with Familial Transthyretic (TTR) Amyloidosis. Although this study is unrelated to Huntington’s disease, it’s a first for gene editing, and the results could have implications for HD and other brain disorders. CRISPR-Cas9 Clustered ... Read more